Galderma is the leading company solely dedicated to skin and advancing the future of dermatology. We deliver an innovative, science-based portfolio of sophisticated brands and services across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Through trusted partnerships with healthcare professionals, we ensure to meet individual consumer and patient needs with superior outcomes.
Unlock the market timeline & signal feed
307 signals in the last 90 days.
The order this company entered each market — oldest to newest
70 active postings
13 active postings
Sign up to see the full signal feed
How Galderma's international expansion compares to its competitors
GaldermaYouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 GaldermaYou | 35 | 0 | -58% | 262 | 35 |
Opérateur de Fabrication FDS - Jour
View postingMontreal, Quebec, Canada · yesterday
General Manager, Injectable Aesthetics
View postingShanghai, Shanghai, China · 2d ago
Opérateur de Production Conditionnement FDS Jour
View postingBaie-d’Urfé, Quebec, Canada · 2d ago
We’re excited to share insights from our new global anti-wrinkle treatment survey, revealing a clear shift in preferences toward high-performance solutions that deliver lasting results and drive innovation in aesthetics.Anti-wrinkle treatments are one of the most common injectable procedures in aesthetics. Results show that healthcare professionals prioritize performance above all. For patients, the value lies in both emotional impact and visible performance, with long-lasting and early results ...
EndedWe’re excited to share insights from our new global anti-wrinkle treatment survey, revealing a clear shift in preferences toward high-performance solutions that deliver lasting results and drive innovation in aesthetics.Anti-wrinkle treatments are one of the most common injectable procedures in aesthetics. Results show that healthcare professionals prioritize performance above all. For patients, the value lies in both emotional impact and visible performance, with long-lasting and early results ...
EndedAt Galderma, the President’s Club Awards are an opportunity to recognize our top-performing Sales colleagues from around the world. This year we held two exceptional events - first, in May, our leading U.S. Sales colleagues gathered in Cap Cana, Dominican Republic, for a well-earned celebration of their remarkable achievements.Then, just this past week, our top Sales colleagues from LATAM, EMEAC and JPAC joined together in Singapore, all in one place for the very first time. These celebrations r ...
EndedGalderma Korea launches Cetaphil SA line for sensitive skin exfoliation. Products include gentle exfoliating cleanser and lotion with triple peeling ingredients and moisturizing components.
Galderma enters biologics market with Nemolizumab, an IL-31 inhibitor for atopic dermatitis and prurigo nodularis, approved in Korea.
Galderma Korea introduced Nemolizumab, an IL-31 inhibitor targeting itch in atopic dermatitis and prurigo nodularis. Clinical trials showed rapid itch relief within 48 hours and significant EASI improvement. Reimbursement application completed, targeting early 2027 launch.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about Galderma's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
